More than 90% of LPs say they require impact funds to perform in-line or better than their generalist private equity benchmark, according to a survey by Rede Partners.
European healthcare investor EQT Life Sciences has closed its inaugural LSP Dementia Fund at €260 million euros, beating its target of €100 million.
OpenView set an ambitious target for Fund VII, aiming for a nearly 80% increase from Fund VI, which closed in October 2020.
The New York firm raised a debut fund of $25m to invest in companies that address affordability, economic mobility and climate change.
Torch Capital's focus on consumer products appears to have lit a fire with investors, as the New York venture firm has closed on more than $200 million, or three times more than it raised for its debut fund.
Sofinnova Partners, a European life sciences venture capital firm, has launched a new investment strategy focused on digital medicine.
The subsidiary of Hercules Capital has formed a new private credit lending program following the failure of Silicon Valley Bank, which was a lender and banker to about half of the venture-backed tech and life sciences start-ups in the US.
SR One Capital Management, a transatlantic biotech VC firm that spun out of GlaxoSmithKline, has closed on more than $600 million for its second fund, beating its $500 million target.
One of the challenges that has emerged as potential buyers explore an acquisition of SVB Financial’s fund of funds platform is continuing access to the top names in venture capital, say sources familiar with the process.
Stifel Financial Corp has hired former Silicon Valley Bank executives Jake Moseley, Matt Trotter and Ted Wilson as managing directors for its venture banking group.